Chicago Equity Partners LLC boosted its position in Eli Lilly and Company (NYSE:LLY) by 37.8% in the 1st quarter, HoldingsChannel.com reports. The firm owned 18,105 shares of the company’s stock after buying an additional 4,965 shares during the period. Chicago Equity Partners LLC’s holdings in Eli Lilly and were worth $1,401,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in LLY. Koshinski Asset Management Inc. boosted its stake in Eli Lilly and by 20.4% in the 4th quarter. Koshinski Asset Management Inc. now owns 7,644 shares of the company’s stock valued at $646,000 after purchasing an additional 1,297 shares during the period. Coastline Trust Co boosted its stake in Eli Lilly and by 28.0% in the 4th quarter. Coastline Trust Co now owns 14,502 shares of the company’s stock valued at $1,225,000 after purchasing an additional 3,175 shares during the period. Benjamin F. Edwards & Company Inc. boosted its stake in Eli Lilly and by 13.3% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 8,321 shares of the company’s stock valued at $703,000 after purchasing an additional 976 shares during the period. Schwab Charles Investment Management Inc. boosted its stake in Eli Lilly and by 3.3% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 4,249,585 shares of the company’s stock valued at $358,928,000 after purchasing an additional 135,951 shares during the period. Finally, Berkshire Asset Management LLC PA boosted its stake in Eli Lilly and by 162.4% in the 4th quarter. Berkshire Asset Management LLC PA now owns 12,171 shares of the company’s stock valued at $1,028,000 after purchasing an additional 7,533 shares during the period. Institutional investors and hedge funds own 78.32% of the company’s stock.
Several equities analysts have weighed in on the company. Zacks Investment Research raised Eli Lilly and from a “hold” rating to a “buy” rating and set a $85.00 price objective for the company in a report on Tuesday, April 3rd. Jefferies Group set a $93.00 price objective on Eli Lilly and and gave the company a “buy” rating in a report on Monday, February 26th. JPMorgan Chase set a $105.00 price objective on Eli Lilly and and gave the company a “buy” rating in a report on Monday, February 26th. HC Wainwright reaffirmed a “buy” rating on shares of Eli Lilly and in a report on Wednesday, April 18th. Finally, TheStreet cut Eli Lilly and from a “b” rating to a “c” rating in a report on Monday, March 5th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have issued a buy rating to the company. Eli Lilly and currently has a consensus rating of “Hold” and an average target price of $93.21.
In related news, major shareholder Lilly Endowment Inc sold 140,000 shares of the business’s stock in a transaction on Friday, May 11th. The stock was sold at an average price of $81.97, for a total transaction of $11,475,800.00. Following the sale, the insider now owns 122,755,804 shares in the company, valued at approximately $10,062,293,253.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Jeffrey N. Simmons sold 9,027 shares of the business’s stock in a transaction on Thursday, May 3rd. The stock was sold at an average price of $78.50, for a total value of $708,619.50. The disclosure for this sale can be found here. Insiders have sold a total of 361,472 shares of company stock valued at $29,328,215 in the last three months. 0.11% of the stock is owned by insiders.
Eli Lilly and stock opened at $81.66 on Friday. The company has a quick ratio of 1.01, a current ratio of 1.41 and a debt-to-equity ratio of 0.64. Eli Lilly and Company has a 52 week low of $81.19 and a 52 week high of $81.89. The firm has a market cap of $89.23 billion, a PE ratio of 19.08, a price-to-earnings-growth ratio of 1.42 and a beta of 0.26.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, April 24th. The company reported $1.34 EPS for the quarter, topping analysts’ consensus estimates of $1.13 by $0.21. Eli Lilly and had a return on equity of 35.37% and a net margin of 4.82%. The company had revenue of $5.70 billion during the quarter, compared to analysts’ expectations of $5.51 billion. During the same quarter in the previous year, the firm earned $0.98 EPS. Eli Lilly and’s revenue was up 9.0% on a year-over-year basis. research analysts forecast that Eli Lilly and Company will post 5.16 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, June 8th. Stockholders of record on Thursday, May 17th will be issued a dividend of $0.5625 per share. The ex-dividend date is Wednesday, May 16th. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.76%. Eli Lilly and’s dividend payout ratio (DPR) is currently 52.57%.
About Eli Lilly and
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.